20/03/2018 - IASCLC Webinar: NSCLC pathology and molecular testing-what should clinicians know

 

IASCLC Webinar: “NSCLC pathology and molecular testing—what should clinicians know”?

The classification of non-small cell lung cancer (NSCLC) has become increasingly accurate over the last years thanks to improvements in the description of histologic features and common molecular alterations of the disease. This higher accuracy is translating into a better diagnosis and management of the disease, but has also entailed a substantial increase in the range of terms for the disease, the technical elements applied for molecular testing, and the logistical considerations for the clinical practice.

International Association for the Study of Lung Cancer
International Association for the Study of Lung Cancer

 

To help clinicians navigate this increasingly complex NSCLC lexicon landscape and identify molecular testing elements that are relevant to their clinical practice, a new webinar published by the International Association of the Study of Lung Cancer (IASLC) is now available. Accessible through their official website, this online seminar also discusses the importance of applying a multidisciplinary approach in optimizing tissue management for molecular studies.

The webinar, presented by Dara L. Aisner, MD, PhD (University of Colorado) and Ramaswamy Govindan, MD (Washington University School of Medicine), can be downloaded or streamed at your convenience through the IASLC website: www.iaslc.org/webinars/nsclc-pathology-and-molecular-testing-what-should-clinicians-know

A summary of the molecular test recommendations can be downloaded from the IASLC website: https://www.iaslc.org/sites/default/files/wysiwyg-assets/26328_testinglung_cancerl_summary_1.18.18_iaslc.pdf

 

Rudy Hovelinck
Diagnostics Manager AstraZeneca

 

NS ID : NS ID BE-1508-RD03/2018-LB Local code 295

Other Inside Diagnostic Articles

About the Author

Rudy Hovelinck

Diagnostics Manager AstraZeneca

rudy.hovelinck@astrazeneca.com

M. +32 (0) 476 42 22 58

Rudy Hovelinck obtained a scientific degree first in biochemistry at Ghent University and later in Molecular Biology at the ULB. Initially exploring the academic world in diverse fields as genetics, protein chemistry and virology, he soon realised that bridging scientific knowledge to the medical world was a more meaningful way of spending his professional life. This journey started in the field of pathology biomarker testing, introducing HER2 IHC and ISH testing for patient therapy selection and continued in the field of molecular oncology. Today at AstraZeneca he works as a diagnostics manager. In this role he is passionately contributing to the successful introduction of novel biomarkers and support current testing strategies for patient selection. In his own time he enjoys travelling with his family exploring the world and spending time close to nature. Specialties: Oncology, Anatomic Pathology, Biomarker Development, Medical Devices.